NO20062883L - Fosfodiesterase-V-inhibitorpreparater - Google Patents

Fosfodiesterase-V-inhibitorpreparater

Info

Publication number
NO20062883L
NO20062883L NO20062883A NO20062883A NO20062883L NO 20062883 L NO20062883 L NO 20062883L NO 20062883 A NO20062883 A NO 20062883A NO 20062883 A NO20062883 A NO 20062883A NO 20062883 L NO20062883 L NO 20062883L
Authority
NO
Norway
Prior art keywords
inhibitorpreparater
phosphodiesterase
pde
women
inhibitors
Prior art date
Application number
NO20062883A
Other languages
English (en)
Norwegian (no)
Inventor
Surendra A Sangekar
Zhiyun Wang
Ping I Lee
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34632926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062883(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20062883L publication Critical patent/NO20062883L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D1/00—Processes for applying liquids or other fluent materials
    • B05D1/18—Processes for applying liquids or other fluent materials performed by dipping
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
    • B05D7/14—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials to metal, e.g. car bodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2202/00—Metallic substrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2258/00—Small objects (e.g. screws)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO20062883A 2003-11-21 2006-06-20 Fosfodiesterase-V-inhibitorpreparater NO20062883L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52473103P 2003-11-21 2003-11-21
PCT/US2004/038887 WO2005051368A2 (en) 2003-11-21 2004-11-18 Phosphodiesterase v inhibitor formulations

Publications (1)

Publication Number Publication Date
NO20062883L true NO20062883L (no) 2006-08-18

Family

ID=34632926

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062883A NO20062883L (no) 2003-11-21 2006-06-20 Fosfodiesterase-V-inhibitorpreparater

Country Status (15)

Country Link
US (2) US20060040962A1 (es)
EP (1) EP1691788A2 (es)
JP (1) JP2007512345A (es)
KR (1) KR20060101762A (es)
CN (1) CN1905860A (es)
AR (1) AR047948A1 (es)
AU (1) AU2004292991A1 (es)
BR (1) BRPI0416202A (es)
CA (1) CA2546248A1 (es)
MX (1) MXPA06005681A (es)
NO (1) NO20062883L (es)
PE (1) PE20050985A1 (es)
TW (1) TW200526664A (es)
WO (1) WO2005051368A2 (es)
ZA (1) ZA200604025B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008000087A (es) * 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
CA2660086C (en) * 2006-08-16 2014-09-16 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
MX2010005198A (es) * 2007-11-12 2010-05-20 Novartis Ag Composiciones liquidas que comprenden valsartan.
ITMI20080227A1 (it) * 2008-02-13 2009-08-14 Felice Vinati '' dispositivo di sicurezza per apparati di sollevamento a fune ''
JP6002562B2 (ja) * 2012-12-05 2016-10-05 横浜ゴム株式会社 面ファスナー付き空気入りタイヤ及びその製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057628A (en) * 1976-04-19 1977-11-08 William L. Wilson Removal of hepatitis associated antigen from plasma
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
CA2098846A1 (en) * 1990-12-21 1992-06-22 David G. Smith Xanthine derivatives
WO1994019351A1 (en) * 1993-02-26 1994-09-01 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5470479A (en) * 1994-06-23 1995-11-28 Westinghouse Electric Corporation Continuous, steady-state, chromatographic separation of gadolinium isotopes
UA46166C2 (uk) * 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
US20030153623A1 (en) * 1998-07-22 2003-08-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble NSAIDs
JP3290970B2 (ja) * 1998-07-22 2002-06-10 山之内製薬株式会社 難溶性ＮＳＡＩＤｓ含有固形製剤
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US6491950B1 (en) * 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
JP3470096B2 (ja) * 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
EP1421084B1 (en) * 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
AU2002360775B9 (en) * 2001-12-28 2008-07-24 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2003101991A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
JP2005529934A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives

Also Published As

Publication number Publication date
BRPI0416202A (pt) 2006-12-26
WO2005051368A2 (en) 2005-06-09
WO2005051368A3 (en) 2006-03-09
TW200526664A (en) 2005-08-16
CA2546248A1 (en) 2005-06-09
JP2007512345A (ja) 2007-05-17
PE20050985A1 (es) 2005-11-26
CN1905860A (zh) 2007-01-31
MXPA06005681A (es) 2006-08-17
AR047948A1 (es) 2006-03-15
ZA200604025B (en) 2008-01-30
US20090074869A1 (en) 2009-03-19
EP1691788A2 (en) 2006-08-23
AU2004292991A1 (en) 2005-06-09
KR20060101762A (ko) 2006-09-26
US20060040962A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
MY128479A (en) (beta)-carboline derivatives useful as inhibitors of phosphodiesterase
HK1113569A1 (en) Pyrazolo
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AR016993A1 (es) Formulaciones intranasales para tratar trastornos sexuales
TW200633980A (en) Pyridones useful as inhibitors of kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
TR200003039T2 (tr) Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
PL1687305T3 (pl) Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
EA200200337A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[4,3-d]ПИРИМИДИНА
NO20092145L (no) Anvendelse av 3-ALFA-Androstandiol, valgfritt i kombinasjon med en PDES-inhibitor, i behandlingen av seksuell dysfunksjon
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
NO20062883L (no) Fosfodiesterase-V-inhibitorpreparater
NO20024364D0 (no) Anvendelse av pyrido [3,2-E]-pyrazinoner som inhibitorer av fosfodiesterase 5 for behandling av erektil dysfunksjon
SE0002934D0 (sv) New aporphine esters and in their use in therapy
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
AU2003258630A1 (en) Pyrimidine derivatives as selective cox-2 inhibitors
HUP0400528A2 (hu) Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására
GB0028245D0 (en) New therapeutic use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application